Dickmann LJ[au] - Search Results

Year	Number of Results
1996	1
2001	2
2002	1
2004	3
2007	1
2008	5
2009	1
2011	2
2012	5
2013	5
2015	1
2016	2
2017	1
2018	1
2019	2
2020	1
2021	0

1

Pharmacogenomics in the age of personalized medicine.

Dickmann LJ, Ware JA. Dickmann LJ, et al. Drug Discov Today Technol. 2016 Sep-Dec;21-22:11-16. doi: 10.1016/j.ddtec.2016.11.003. Drug Discov Today Technol. 2016. PMID: 27978982 Review.

2

Can Digital Health Enable Higher Quality Real-World Evidence-Based Decisions?

Dickmann LJ, Kothare PA. Dickmann LJ, et al. Clin Pharmacol Ther. 2019 Jul;106(1):45-46. doi: 10.1002/cpt.1440. Epub 2019 Apr 23. Clin Pharmacol Ther. 2019. PMID: 31013352 No abstract available.

3

Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy.

Reyner E, Lum B, Jing J, Kagedal M, Ware JA, Dickmann LJ. Reyner E, et al. Among authors: dickmann lj. Clin Transl Sci. 2020 Mar;13(2):410-418. doi: 10.1111/cts.12726. Epub 2019 Dec 12. Clin Transl Sci. 2020. PMID: 31729137 Free PMC article.

4

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.

Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L. Evers R, et al. Among authors: dickmann lj. Drug Metab Dispos. 2013 Sep;41(9):1598-609. doi: 10.1124/dmd.113.052225. Epub 2013 Jun 21. Drug Metab Dispos. 2013. PMID: 23792813 Review.

5

Racial and Ethnic Composition of Cancer Clinical Drug Trials: How Diverse Are We?

Dickmann LJ, Schutzman JL. Dickmann LJ, et al. Oncologist. 2018 Feb;23(2):243-246. doi: 10.1634/theoncologist.2017-0237. Epub 2017 Dec 19. Oncologist. 2018. PMID: 29259072 Free PMC article.

6

Evaluation of Fluorophotometry to Assess the Vitreal Pharmacokinetics of Protein Therapeutics.

Dickmann LJ, Yip V, Li C, Abundes J Jr, Maia M, Young C, Stainton S, Hass PE, Joseph SB, Prabhu S, Boswell CA. Dickmann LJ, et al. Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6991-9. doi: 10.1167/iovs.15-17457. Invest Ophthalmol Vis Sci. 2015. PMID: 26513505

7

CYP2C9 genetic polymorphisms and warfarin.

Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. Redman AR, et al. Among authors: dickmann lj. Clin Appl Thromb Hemost. 2004 Apr;10(2):149-54. doi: 10.1177/107602960401000205. Clin Appl Thromb Hemost. 2004. PMID: 15094935 Free article.

8

An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway.

Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE. Wang Z, et al. Among authors: dickmann lj. Mol Pharmacol. 2012 Apr;81(4):498-509. doi: 10.1124/mol.111.076356. Epub 2011 Dec 28. Mol Pharmacol. 2012. PMID: 22205755 Free PMC article.

9

IL-22 regulates iron availability in vivo through the induction of hepcidin.

Smith CL, Arvedson TL, Cooke KS, Dickmann LJ, Forte C, Li H, Merriam KL, Perry VK, Tran L, Rottman JB, Maxwell JR. Smith CL, et al. Among authors: dickmann lj. J Immunol. 2013 Aug 15;191(4):1845-55. doi: 10.4049/jimmunol.1202716. Epub 2013 Jul 8. J Immunol. 2013. PMID: 23836059 Free article.

10

Differential activation of CYP2C9 variants by dapsone.

Hummel MA, Dickmann LJ, Rettie AE, Haining RL, Tracy TS. Hummel MA, et al. Among authors: dickmann lj. Biochem Pharmacol. 2004 May 15;67(10):1831-41. doi: 10.1016/j.bcp.2004.01.017. Biochem Pharmacol. 2004. PMID: 15130760

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results